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Summary
Hyponatraemia is the most commonly encountered electrolyte disturbance in neurological high dependency and intensive 
care units. Cerebral salt wasting (CSW) is the most elusive and challenging of the causes of hyponatraemia, and it is vital 
to distinguish it from the more familiar syndrome of inappropriate antidiuretic hormone (SIADH). Managing CSW requires 
correction of the intravascular volume depletion and hyponatraemia, as well as mitigation of on-going substantial sodium 
losses. Herein we describe a challenging case of CSW requiring large doses of hypertonic saline and the subsequent 
substantial benefit with the addition of fludrocortisone.
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Learning points:
•	 The diagnosis of CSW requires a high index of suspicion. Distinguishing it from SIADH is essential to enable prompt 
treatment in order to prevent severe hyponatraemia.
•	 The hallmarks of substantial CSW are hyponatraemia, reduced volume status and inappropriately high renal 
sodium loss.
•	 Substantial volumes of hypertonic saline may be required for a prolonged period of time to correct volume and 
sodium deficits.
•	 Fludrocortisone has a role in the management of CSW. It likely reduces the doses of hypertonic saline required and 
can maintain serum sodium levels of hypertonic saline.
Background
Cerebral salt wasting (CSW) is an uncommon cause of 
hyponatraemia and is particularly challenging to manage. 
Making the diagnosis rapidly is vital as its treatment 
requires volume resuscitation and sodium restoration 
rather than the water restriction used for the more 
commonly observed SIADH. Hyponatraemia is common 
in neurosurgical patients and is associated with substantial 
morbidity and mortality. Diagnosis of the cause and its 
correction are essential to prevent severe hyponatraemia, 
which can substantially worsen cerebral oedema and 
increase the risk of seizures.
Case presentation
A 44-year-old male with no substantial medical history 
was injured falling off his road bike at 25 mph and 
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sustained a traumatic brain injury resulting in a marked 
expressive dysphasia. CT brain demonstrated a small left 
subdural haematoma, left temporal contusion and right 
petrous temporal bone fracture. He did not require surgical 
intervention. Forty eight hours after injury he developed 
a lower motor neurone facial weakness secondary to the 
temporal bone fracture, therefore dexamethasone was 
commenced.
On Day 5 of admission his sodium level fell. Initially 
attributed to SIADH, his sodium continued to fall rapidly 
despite fluid restriction and slow sodium tablets. Baseline 
paired serum and urine osmolality were 265 and 595 
respectively with urine sodium of 191 mmol/L. He was 
referred to endocrinology who suspected a diagnosis 
of CSW on the basis of failure of resolution with fluid 
restriction, low JVP and high urine output. Urine 
output assessment was challenging to interpret initially 
due to extreme confusion, and agitation preventing 
catheterisation but his urine output was in excess of 
3 L a day at this point despite a 1.5 L fluid restriction. 
During this time the patient recalls having excessive 
thirst and a craving for the salt tablets, which he later 
found unpalatable.
Investigation
Despite hypertonic saline (1.8% saline) being 
commenced, his sodium continued to fall, with 
increased cerebral oedema and worsening confusion. 
This combination necessitated admission to intensive 
care with a sodium nadir of 116 mmol/L. A graph of 
his serum sodium, urine sodium and daily intravenous 
sodium is shown in Fig. 1.
Treatment
Infusion of 5% saline (>950 mEq of sodium required in first 
24 h in ITU) restored serum sodium to low normal levels 
within 72 h (sodium 134 mmol/L). During his intensive 
care admission he also required inotropic support which 
further highlights the extent of his volume depletion. 
Following the stabilisation of his sodium levels he was 
stepped back down to the neurosurgical high dependency 
unit. However, his urinary sodium remained persistently 
elevated peaking at 254 mmol/L, (urine osmolality 
710 mmol/kg) serum sodium fell to 125 mmol/L despite 
hypertonic saline and he required substantial volume 
replacement (equivalent of more than 4 L/day of 1.8% 
saline). Urine output remained persistently high between 
3 and 5 L a day over this time.
Fludrocortisone was therefore introduced at 75 µg bd 
and ultimately increased to 150 µg bd, which resulted in a 
substantial (threefold) fall in requirements for hypertonic 
saline that was still required for another 7 days. His sodium 
remained stable around 130 mmol/L on fludrocortisone 
alone and he was discharged home 25 days post injury. 
Fludrocortisone was continued for the next four months.
The dexamethasone initiated at 48 hours was continued 
for a 1-week course. As a baseline cortisol taken 24 h post 
the final dexamethasone was 94 nmol/L, he was maintained 
on hydrocortisone 10 mg bd which was continued until 
after discharge. A post discharge short synacthen test was 
normal and hydrocortisone was then stopped.
Outcome and follow-up
It took four months to wean him off the fludrocortisone 
without the occurrence of rebound hyponatraemia 
suggestive of on-going, albeit mild, CSW. Intriguingly, the 
attempt in the week after he developed peripheral oedema 
on fludrocortisone was successful and he has remained 
stable off fludrocortisone for three months. Despite an 
otherwise excellent recovery, he has since developed 
hypertension and has observed his sweat appears to be 
less salty, indicating perhaps on-going mild disturbance 
of sodium handling.
Discussion
CSW is a disorder of sodium and water homoeostasis 
which occurs as a result of cerebral disease in the setting of 
normal renal function. It was first described over 65 years 
ago by Peters et al. (1) several years before the SIADH was 
first described. Unlike SIADH, CSW results in inappropriate 
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Figure 1
Serum sodium, urine sodium and daily intravenous sodium.
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primary sodium losses which are not related to volume 
expansion. Despite our awareness of CSW for several 
decades the pathogenesis remains unclear; however atrial, 
brain C type and dendroapsis natriuretic peptides have 
been implicated (2, 3). The release of these peptides may 
arise from increased atrial stretch and increased ventricular 
load from sympathetic outflow surges (4) whereas direct 
trauma to the brain releases BNP. Furthermore ANP and 
BNP may be released by the hypothalamus as a protective 
mechanism against rising intracranial pressure (2). Indeed 
BNP appears to be the driving factor of CSW following 
sub-arachnoid haemorrhage (2).
It is postulated that these natriuretic peptides inhibit 
sympathetic outflow, the renin–aldosterone system and 
the production of vasoconstrictor peptides. This results 
in a reduction in the efficacy of aldosterone and leads 
to a substantial reduction in the ability of the kidneys 
to resorb sodium. Direct interference to the sympathetic 
innervation to the kidney has also been postulated in 
the pathogenesis of CSW (5). As a result, there can be 
substantial impairment of sodium handling.
Whilst CSW should be considered in any at-risk 
patient with abnormal sodium handling in the absence of 
renal dysfunction, adrenal insufficiency or inappropriate 
volume expansion, it is the more severe forms that likely 
require specialist endocrine input. Severe CSW will likely 
result in a very high urine sodium concentration, a high 
urine output leading to a high serum urea, postural 
hypotension and a low central venous pressure. High 
fractional excretion of uric acid occurs in both SIADH and 
CSW; however, this can persist in CSW despite correction 
of hyponatraemia unlike in SIADH (6).
The management of profound CSW is therefore 
correction of intravascular volume depletion and 
hyponatraemia, and mitigation of the on-going high 
urinary sodium loss. The Na losses are such that 
hypertonic saline is usually necessary. Close monitoring 
of hypertonic saline is essential to prevent overly 
rapid correction of hyponatraemia, which might 
result in osmotic myelinolysis. Addressing these issues 
reinforces the importance of distinguishing CSW from 
the familiar cause of hyponatraemia SIADH; although 
the distinction can be challenging, it is absolutely 
essential as the treatments for the two conditions are so 
fundamentally different.
Pharmacological intervention also has a role. 
Fludrocortisone is recommended as a potential 
therapeutic option in CSW. In this reported case, the 
addition of fludrocortisone did appear to reduce the need 
for on-going boluses of hypertonic saline, likely through 
its mineralocorticoid potency which encourages sodium 
retention. Careful monitoring is still essential as overly 
aggressive fluid and sodium administration combined 
with mineralocorticoids can cause volume overload, 
leading to pulmonary oedema and hypertension. 
Tolvaptan a competitive V2 receptor antagonist is a recent 
novel treatment for hyponatraemia. However current 
opinion is that it should not be used in CSW as it is likely 
to exacerbate fluid depletion.
In conclusion, this report highlights the need 
for vigilance in encountering hyponatraemia in the 
neurosurgical patient, and the diagnostic challenge that is 
CSW. Furthermore, it clearly demonstrates the substantial 
volumes of hypertonic saline that can be required and 
how fludrocortisone can be used to mitigate this. It is 
noteworthy that although we have known about CSW 
for several decades several fundamental questions have 
yet to be answered, the most important of which are how 
cerebral injury leads to the release of excessive amounts 
of natriuretic peptides and why this occurs in only a small 
subset of cerebral injury types.
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